Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens

ABSTRACT Objective To compare viral suppression in treatment-naïve adults starting antiretroviral therapy with dolutegravir (50mg)- and efavirenz (600mg)-based regimens. Methods We analyzed secondary data from Brazilian health information systems of people living with human immunodeficiency viru...

Full description

Bibliographic Details
Main Authors:	Gabriella Jomara da Silva, Cássia Cristina Pinto Mendicino, Cristiane Aparecida Menezes de Pádua, Unaí Tupinambás
Format:	Article
Language:	English
Published:	Instituto Israelita de Ensino e Pesquisa Albert Einstein 2023-05-01
Series:	Einstein (São Paulo)
Subjects:	HIV-1 Viral load Sustained virologic response Effectiveness Dolutegravir Efavirenz Drug therapy, combination Antiretroviral therapy, highly active Anti-HIV agents
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082023000100213&lng=en&tlng=en

Similar Items

A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China
by: Mingli Zhong, et al.
Published: (2023-01-01)

Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
by: John C. Chapola, et al.
Published: (2023-09-01)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
by: Dowers E, et al.
Published: (2018-11-01)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
by: Chang Huang, et al.
Published: (2023-03-01)

Dolutegravir for second-line treatment: Programmatic implications of new evidence
by: Ying Zhao, et al.
Published: (2022-09-01)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
by: Kairoonisha Mahomed, et al.
Published: (2020-07-01)

The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review
by: Aprilianti S, et al.
Published: (2024-01-01)

Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil
by: T. Vanni, et al.
Published: (2007-07-01)

Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials
by: Yuanlu Shu, et al.
Published: (2021-05-01)

Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART; a comparative cross-sectional study
by: Mohammed Jemal, et al.
Published: (2023-12-01)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
by: Spagnuolo V, et al.
Published: (2019-01-01)

Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir
by: Supphachoke Khemla, et al.
Published: (2023-04-01)

Evaluation of the Side Effects of Antiretroviral Treatment
by: Sedef BAŞGÖNÜL, et al.
Published: (2018-12-01)

Growth, weight gain and BMI in virally suppressed children on antiretroviral therapy with specific reference to dolutegravir
by: Erik Belfrage, et al.
Published: (2023-07-01)

Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies Among HIV Patients: A Retrospective Cohort Study
by: Ayal MA, et al.
Published: (2023-04-01)

Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study
by: Henry Zakumumpa, et al.
Published: (2022-08-01)

Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis
by: Diana B. Pedral-Sampaio, et al.

A Case Series of Efavirenz Induced Gynaecomastia
by: Charu Jain , Neha Sharma , Uma Advani , Lokendra Sharma , Munesh Kumar , Monica Jain
Published: (2023-08-01)

Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study
by: Roberta Gagliardini, et al.
Published: (2022-03-01)

Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi’s National HIV Treatment Program
by: Hope Kanise, et al.
Published: (2023-12-01)

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
by: Alberto Borghetti, et al.
Published: (2019-01-01)

EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN
by: Farzana Batool, et al.
Published: (2021-10-01)

CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil
by: TALISE E. MÜLLER, et al.

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
by: Adelline Twimukye, et al.
Published: (2021-11-01)

Revisiting efavirenz in the era of dolutegravir: Low-dose efavirenz, a viable alternative capable of holding its own against dolutegravir-based regimens
by: Sumit Arora, et al.
Published: (2023-01-01)

Outcomes of severely ill patients with AIDS treated with efavirenz or dolutegravir: a multicenter, observational study
by: Carlos Brites, et al.
Published: (2024-02-01)

Effect of dolutegravir-based versus efavirenz-based antiretroviral therapy on excessive weight gain in adult treatment-naïve HIV patients at Matsanjeni health center, Eswatini: a retrospective cohort study
by: Didier M. Mukuna, et al.
Published: (2024-01-01)

Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study
by: Jing Xiao, et al.
Published: (2022-04-01)

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial [version 1; peer review: 2 approved, 1 approved with reservations]
by: Zimasa Gcwabe, et al.
Published: (2021-02-01)

Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
by: Muche Belete A, et al.
Published: (2021-02-01)

Clinical experience with dolutegravir: efficacy, safety, and tolerability
by: Isabel Furtado, et al.
Published: (2022-01-01)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
by: Zamora FJ, et al.
Published: (2019-10-01)

Efavirenz: History, Development and Future
by: Bárbara Costa, et al.
Published: (2022-12-01)

Will Drug Resistance against Dolutegravir in Initial Therapy Ever Occur?
by: Mark eWainberg, et al.
Published: (2015-04-01)

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation
by: Dominique L. Braun, et al.
Published: (2020-11-01)

Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe
by: Vinie Kouamou, et al.
Published: (2023-09-01)

Effect of dolutegravir-based first-line antiretroviral therapy on weight and body mass index among adult people living with HIV on follow up at health facilities in Hawassa city administration, Southern Ethiopia: a retrospective cohort study
by: Agete Tadewos Hirigo, et al.
Published: (2023-12-01)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
by: Lisi Deng, et al.
Published: (2022-01-01)

Prevalence of and Factors Associated with Hypertension Among Adults on Dolutegravir-Based Antiretroviral Therapy in Uganda: A Cross Sectional Study
by: Kasoma Mutebi R, et al.
Published: (2023-04-01)

Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model
by: Ezechiel Ngoufack Jagni Semengue, et al.
Published: (2022-12-01)